Market reactionShares rose 10% on Nov 4.
NovoCure is a commercial-stage company that sells Optune, wearable devices that treat tumors with electric fields, approved for glioblastoma, lung cancer, mesothelioma and pancreatic cancer.
NovoCure depends on Optune Gio while expanding TTFields into other cancers. Optune Pax approvals support diversification, but TRIDENT's survival miss weakened earlier use in glioblastoma. The expected Q4 2026 FDA brain-metastases decision remains the next major opportunity. Cash, cash equivalents and short-term investments reached $463.5 million at September 30, 2026. Management conditionally expects funding for at least the next 12 months; $200.0 million is borrowed, and further facility draws are unavailable. Commercial expansion must translate into sustained growth without undermining financial progress.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves TTFields for brain metastases from lung cancer
Does FDA approve TTFields for brain metastases from non-small cell lung cancer with a commercially useful label?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Gio drives growth; Pax adoption weakens ahead of brain-metastases decision
Three approved TTFields devices, $710M+ revenue guidance, but GBM expansion just failed — Optune Lua's brain-mets PMA is now the growth thesis
Three approved TTFields devices, a TRIDENT miss in GBM, and a Q4 FDA decision on NSCLC brain mets that will test whether the platform's expansion can compensate
Optune Lua's NSCLC brain metastases PMA decision will test whether TTFields can expand beyond its Optune Gio base into a larger lung cancer population
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.